Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma CDMO offers integrated end-to-end solutions for development & commercialization of intermediates & APIs for small molecules.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    veranova-m-2025-06-30

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Tafasitamab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Incyte Announces FDA Approval of Monjuvi for Lymphoma
    Incyte Announces FDA Approval of Monjuvi for Lymphoma

    19 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250615896694/en/Incyte-Announces-FDA-Approval-of-Monjuvi-tafasitamab-cxix-in-Combination-with-Rituximab-and-Lenalidomide-for-Patients-with-Relapsed-or-Refractory-Follicular-Lymphoma

    BUSINESSWIRE
    19 Jun 2025
    Share Share
    Specialised Therapeutics Expands Incyte Deal With 2 Therapies
    Specialised Therapeutics Expands Incyte Deal With 2 Therapies

    12 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/specialised-therapeutics-expands-partnership-with-incyte-to-include-two-additional-therapies-for-hard-to-treat-conditions-302479723.html

    PR NEWSWIRE
    12 Jun 2025
    Share Share
    InnoCare’s Minjuvi Combo Approved in China
    InnoCare’s Minjuvi Combo Approved in China

    21 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250521528560/en/InnoCare-Announces-the-Approval-of-Minjuvi-Tafasitamab-in-Combination-with-Lenalidomide-for-the-treatment-of-Adult-Patients-with-Relapsed-or-Refractory-Diffuse-Large-B-Cell-Lymphoma-in-China

    BUSINESSWIRE
    21 May 2025
    Share Share
    Incyte Monjuvi Data Shows Improved Survival In Follicular Lymphoma
    Incyte Monjuvi Data Shows Improved Survival In Follicular Lymphoma

    10 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241210526828/en

    BUSINESSWIRE
    10 Dec 2024
    Share Share
    Incyte's Monjuvi proves its worth in follicular lymphoma
    Incyte's Monjuvi proves its worth in follicular lymphoma

    26 Nov 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/incytes-monjuvi-wins-big-follicular-lymphoma-phase-3-padding-upcoming-fda-filing

    FIERCE PHARMA
    26 Nov 2024
    Share Share
    Incyte to Present New Tafasitamab Data at 2024 ASH Annual Meeting
    Incyte to Present New Tafasitamab Data at 2024 ASH Annual Meeting

    25 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241125630696/en

    BUSINESSWIRE
    25 Nov 2024
    Share Share